INZY - Inozyme Pharma, Inc.

QQQ $ 474.86 $ 2.12 (0.45 %)

DIA $ 414.87 $ 2.97 (0.72 %)

SPY $ 561.82 $ 2.92 (0.52 %)

TLT $ 100.40 $ 0.27 (0.27 %)

GLD $ 238.66 $ 2.35 (0.99 %)

Previous Close

$ 6

Open

Bid

$ 5.99 x 200

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 2.69 - $ 7.80

Volume

399,188

Average Volume

Market Cap

376.41M

Beta (5Y Monthly)

$ 0.95

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-06-2024	06-30-2024	10-Q
2	05-07-2024	03-31-2024	10-Q
3	03-12-2024	12-31-2023	10-K
4	11-07-2023	09-30-2023	10-Q
5	08-08-2023	06-30-2023	10-Q
6	05-09-2023	03-31-2023	10-Q
7	03-22-2023	12-31-2022	10-K
8	11-10-2022	09-30-2022	10-Q
9	08-15-2022	06-30-2022	10-Q
10	05-10-2022	03-31-2022	10-Q
11	03-15-2022	12-31-2021	10-K
12	11-09-2021	09-30-2021	10-Q
13	08-11-2021	06-30-2021	10-Q
14	05-12-2021	03-31-2021	10-Q
15	03-25-2021	12-31-2020	10-K
16	11-12-2020	09-30-2020	10-Q
17	09-03-2020	06-30-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

why-analyst-says-rare-disease-focused-inozyme-pharma-stock-could-be-worth-a-look

Why Analyst Says Rare Disease-Focused Inoz...
09/12/2024 18:35:59

Stifel initiates coverage on Inozyme Pharma with a Buy rating and a $16 price target, highlighting INZ-701's potential to t...

this-autonation-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday

This AutoNation Analyst Begins Coverage On...
09/12/2024 11:43:39

Stifel Initiates Coverage On Inozyme Pharm...
09/12/2024 10:46:24

Stifel analyst Dae Gon Ha initiates coverage on Inozyme Pharma (NASDAQ:INZY) with a Buy rating and announces Price Target of...

why-nikola-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-mondays-mid-day-session

Why Nikola Shares Are Trading Lower By Aro...
08/19/2024 17:37:46

zim-integrated-shipping-services-posts-upbeat-earnings-joins-fubotv-foghorn-therapeutics-and-other-big-stocks-moving-higher-on-monday

ZIM Integrated Shipping Services Posts Upb...
08/19/2024 14:25:31

Jefferies Assumes Inozyme Pharma at Buy, R...
08/13/2024 10:44:04

Jefferies analyst Maury Raycroft assumes Inozyme Pharma (NASDAQ:INZY) with a Buy rating and raises Price Target to $17.

HC Wainwright & Co. Reiterates Buy on Inoz...
08/08/2024 10:40:56

HC Wainwright & Co. analyst Edward White reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $14 price target.

Needham Reiterates Buy on Inozyme Pharma, ...
08/06/2024 17:45:10

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

Inozyme Pharma Q2 EPS $(0.44) Misses $(0.3...
08/06/2024 12:39:05

Inozyme Pharma (NASDAQ:INZY) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0....

Wedbush Reiterates Outperform on Inozyme P...
07/26/2024 15:44:29

Wedbush analyst David Nierengarten reiterates Inozyme Pharma (NASDAQ:INZY) with a Outperform and maintains $15 price target.

Inozyme Pharma Announces Preclinical Data ...
07/25/2024 12:37:47

HC Wainwright & Co. Reiterates Buy on Inoz...
07/02/2024 14:37:51

HC Wainwright & Co. analyst Edward White reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $14 price target.

Inozyme Pharma shares are trading higher a...
07/02/2024 12:34:53

Inozyme Pharma Announces FDA Fast Track De...
07/02/2024 12:33:05

Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutica...

Wells Fargo Initiates Coverage On Inozyme ...
05/30/2024 14:53:30

Wells Fargo analyst Tiago Fauth initiates coverage on Inozyme Pharma (NASDAQ:INZY) with a Overweight rating and announces Pr...

Inozyme Pharma To Present Phase 1/2 Trial ...
05/23/2024 12:34:54

Needham Reiterates Buy on Inozyme Pharma, ...
05/08/2024 10:17:16

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

Inozyme Pharma Q1 EPS $(0.38) Misses $(0.3...
05/07/2024 12:49:33

Inozyme Pharma (NASDAQ:INZY) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0....

12-health-care-stocks-moving-in-mondays-after-market-session

12 Health Care Stocks Moving In Monday's A...
04/29/2024 20:31:14

Needham Reiterates Buy on Inozyme Pharma, ...
04/10/2024 10:43:01

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.